Press archive

---

08/31/10, Research & Development Bayer´s Rivaroxaban Successfully Meets Primary Efficacy Outcome and Demonstrates Similar Safety to Standard Therapy in Phase III EINSTEIN-DVT Non-Inferiority Study Results from EINSTEIN-DVT Study Presented at European Society of Cardiology Congress 2010 more

---

08/04/10, Bayer HealthCare Bayer’s Rivaroxaban Meets Primary Endpoint in Long-Term Phase III EINSTEIN-DVT Study Rivaroxaban shows superiority to standard therapy in net clinical benefit, a secondary endpoint of the study / Rivaroxaban well tolerated in this long-term trial / Full data set to be presented at Hot Line Session at ESC 2010 more

---

08/04/10, Diagnostic imaging FDA Accepts New Drug Application for Gadovist® 1.0 Injection in Magnetic Resonance Imaging more

---

07/29/10, Bayer HealthCare Bayer increases sales and earnings in the second quarter Sales grow by 14.6 percent to EUR 9,179 million / EBITDA before special items up 8.6 percent to EUR 1,917 million / Core earnings per share increase by 9.5 percent to EUR 1.15 / Investing in the future: research and development expenses in 2010 to reach a new high of approximately EUR 3.1 billion / Group outlook confirmed for 2010 more

---

07/20/10, Cancer “Advances in Renal Cancer” Journalists’ Award 2011 announced Bayer HealthCare and Kidney Cancer Association (KCA) honor medical reporting about renal cancer more

---

07/19/10, Gynecology/Andrology Bayer Schering Pharma enters strategic partnership with The People’s Liberation Army General Hospital in China Special focus on joint research programs in the field of gynecological diseases more

---

07/15/10, Gynecology/Andrology Experts confirm favorable benefit-risk profile of combined oral contraceptives Combined oral contraceptives are one of the safest, most reliable and most convenient options to prevent unplanned pregnancies / All combined oral contraceptives are associated with an increased risk of venous thromboembolism / Risk factor information is essential in deciding whether a combined oral contraceptive is a suitable contraceptive choice more

---

06/21/10, Erection disturbance New erectile dysfunction treatment STAXYN™ approved in the U.S. Orodispersible formulation of Levitra® (vardenafil HCI) soon available more

---

06/17/10, Cancer Bayer Schering Pharma and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics Collaboration Focuses on the Discovery and Development of Multiple Antibody, Protein and Small Molecule Agents Targeting the Wnt Pathway more

---

06/17/10, Cardiovascular diseases Results from Phase III EINSTEIN-DVT Study with Bayer’s Rivaroxaban to be Presented at Hot Line Session at ESC 2010 more

---

06/14/10, Cancer Phase III Trial of Nexavar® in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival Positive Secondary Endpoint of Progression Free Survival / Clinical Trial Program in Lung Cancer Ongoing more

---

06/08/10, Betaferon/Betaseron Study Supports Long-Term Safety Profile of Betaferon® for Multiple Sclerosis Over 16 Years Study results published in Neurology provide the longest follow-up data among patients with multiple sclerosis more

---

05/21/10, Cancer Nexavar® Data To Be Presented at 46th American Society of Clinical Oncology Annual Meeting more

---

05/18/10, Cardiovascular diseases Bayer Presents New Riociguat Phase II Data First Phase II study in patients with pulmonary hypertension owing to interstitial lung disease meets primary objectives / First long-term extension data of Phase II study in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension show sustained improvement in exercise capacity more

---

05/17/10, Research & Development Bayer Schering Pharma Enhances U.S. Research Strategy with New Innovation Center New U.S. Innovation Center in San Francisco’s Mission Bay will focus on developing partnerships with academic research institutions and small life science firms more

---

05/07/10, Gynecology/Andrology Bayer receives approval for its new oral contraceptive in the U.S. The first and only contraceptive to bring estradiol valerate together with dienogest in a new dosing regimen / Product will be marketed as Natazia® in the U.S. more

---

05/07/10, Cancer Bayer Schering Pharma Initiates Phase III Trial of Regorafenib in Metastatic Colorectal Cancer more

---

05/05/10, Gynecology/Andrology Bayer Schering Pharma and EndoCeutics Enter into a Global Agreement for the Development and Commercialization of Treatment for Vaginal Atrophy and Female Sexual Dysfunction more

---

04/29/10, Bayer HealthCare Bayer achieves strong gains in sales and earnings Sales advance by 5.3 percent to EUR 8,316 million / EBITDA before special items climbs by 13.2 percent to EUR 1,918 million / Net income up 63.1 percent to EUR 693 million / Core earnings per share increase by 31.9 percent to EUR 1.20 / Group outlook raised for 2010 more

---

04/21/10, Bayer HealthCare Dr. Jörg Reinhardt appointed new CEO of Bayer HealthCare Arthur Higgins to leave the company at the end of April / Dr. Marijn Dekkers to head the subgroup temporarily as of May 1 more